From Medscape Oncology

Conference Coverage From The

European Society for Medical Oncology (ESMO) Annual Meeting 2020

September 19 - 21, 2020; Virtual Meeting

September 19 - 21, 2020 Virtual Meeting

ESMO 2020 Sotorasib Is a 'Triumph of Drug Discovery' in Cancer The drug inhibits KRAS p.G12C-mutant tumors, which are seen in about 13% of patients with non-small cell lung cancer.
Medscape Medical News, September 21, 2020
ESMO 2020 Oncologist Distress and Burnout Has Increased During COVID Feelings of distress and burnout among oncology professionals have increased during the COVID-19 pandemic and "urgent measures" are needed to improve well-being, suggests the largest survey to date.
Medscape Medical News, September 14, 2020

Conference News

ESMO 2020 Surveillance After CRC Resection Does Not Improve Survival
Medscape Medical News, October 13, 2020
ESMO 2020 Chemoradiation Boosts Glioblastoma Survival in Real-World Setting
Medscape Medical News, October 13, 2020
ESMO 2020 Clinical Factors and Treatment Tied to COVID-19 Mortality
Medscape Medical News, October 9, 2020
ESMO 2020 Divergent Findings With Paclitaxel and Nab-Paclitaxel in TNBC
Medscape Medical News, September 28, 2020
ESMO 2020 Pembrolizumab Shows Activity in Select Rare Sarcomas
Medscape Medical News, September 24, 2020
ESMO 2020 New Drug for Prostate Cancer: Ipatasertib, an AKT Inhibitor
Medscape Medical News, September 24, 2020
ESMO 2020 Lorlatinib: Another First-Line Option for ALK-Positive NSCLC?
Medscape Medical News, September 23, 2020
ESMO 2020 'Paradigm Shift' in Gastric Junction Cancers With Nivolumab
Medscape Medical News, September 23, 2020
ESMO 2020 A Glimmer of Hope for Immunotherapy in SCLC?
Medscape News UK, September 23, 2020
ESMO 2020 New First-Line Standard of Care for Esophageal Cancer?
Medscape Medical News, September 22, 2020

ESMO 2020 Not All Prostate Cancer Mutations Created Equal for Olaparib
Medscape News UK, September 22, 2020
ESMO 2020 Survey Quantifies COVID-19's Impact on Oncology
Medscape Medical News, September 21, 2020
ESMO 2020 Abemaciclib Cuts Early Recurrence in High-risk Breast Cancer
Medscape Medical News, September 21, 2020
ESMO 2020 Lenvatinib Combo May Offer Hope After Immunotherapy in Melanoma
Medscape Medical News, September 21, 2020
ESMO 2020 Sotorasib Is a 'Triumph of Drug Discovery' in Cancer
Medscape Medical News, September 21, 2020
ESMO 2020 First-in-Class ADC Ups Survival in mTNBC
Medscape Medical News, September 21, 2020
ESMO 2020 Nivo-Cabo Combo Joins Advanced RCC Treatment Ranks
Medscape Medical News, September 21, 2020
ESMO 2020 Oncologist Distress and Burnout Has Increased During COVID
Medscape Medical News, September 14, 2020
ESMO 2020 The March of Immunotherapy Continues at ESMO 2020
Medscape Medical News, September 14, 2020

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

ctDNA Shows Promise for Assessing Lung Cancer Treatment Response
Mark G. Kris, MD
Osimertinib as Adjuvant Therapy in EGFR-Mutant Lung Cancer
Mark G. Kris, MD
Highlights in Ovarian Cancer From ESMO 2020
Susana Banerjee, MBBS, MA, PhD, FRCP
Renal Cell Carcinoma Highlights From ESMO 2020
Robert J. Motzer, MD
Prostate Cancer Highlights From ESMO 2020
Johann S. de Bono, MD, PhD
Breakthroughs in Melanoma From ESMO Virtual Congress 2020
Caroline Robert, MD, PhD
David Kerr on ESMO's Most Important Colorectal Cancer Trials
David J. Kerr, CBE, MD, DSc
An Important Negative Study for Post-op RT in Lung Cancer
Mark G. Kris, MD
CDK4/6 Inhibitors in Early Breast Cancer: Different Trial Results Means Good Science
Kathy D. Miller, MD
Innate Immune Response Produces 'Phenomenal' Breast Cancer Control
Kathy D. Miller, MD
ESMO: How Cancer Services Were Hit by COVID-19 First Wave
Prof Karol Sikora
For Immunotherapy in TNBC, Nab-paclitaxel Is a Must
Kathy D. Miller, MD
ESMO: STIMULI Optimism Despite Trial Data Disappointment
Prof Sanjay Popat
ESMO: monarchE Abemaciclib 'Landmark' HR+ Breast Cancer Study
Prof Stephen Johnston
Burnout and Distress: ESMO Hears How COVID-19 Impacted Oncologists
Dr Susana Banerjee

Popular News from ESMO 2019

One in Two Patients With Metastatic Melanoma Alive After 5 Years With the combination of ipilimumab and nivolumab, 50% of patients are still alive after 5 years, a survival rate remarkably higher than that seen with either agent alone.
Medscape Medical News, Sep 28, 2019
PARP Inhibitors Move Into First-Line for Ovarian Cancer New results with three different drugs in patients with newly diagnosed ovarian cancer "strongly justify moving PARP inhibitors into first-line therapy," says expert.
Medscape Medical News, Sep 29, 2019
Burnout Common Among Oncologists: What to Do? Three surveys have found a high prevalence of burnout among oncologists, and a session at the recent ESMO meeting included discussion about what steps can be implemented to combat it.
Medscape Medical News, Oct 08, 2019

Previous Conferences